Terms: = Ovarian cancer AND SFPQ, PSF, 6421, ENSG00000116560, P23246 AND Treatment
4 results:
1. Predicting tumor response and outcome of second-look surgery with
Aide N; Fauchille P; Coquan E; Ferron G; Combe P; Meunier J; Alexandre J; Berton D; Leary A; De Rauglaudre G; Bonichon N; Pujade Lauraine E; Joly F
Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1998-2008. PubMed ID: 33221969
[TBL] [Abstract] [Full Text] [Related]
2. Splicing factor proline- and glutamine-rich (sfpq) protein regulates platinum response in ovarian cancer-modulating SRSF2 activity.
Pellarin I; Dall'Acqua A; Gambelli A; Pellizzari I; D'Andrea S; Sonego M; Lorenzon I; Schiappacassi M; Belletti B; Baldassarre G
Oncogene; 2020 May; 39(22):4390-4403. PubMed ID: 32332923
[TBL] [Abstract] [Full Text] [Related]
3. Could HE4 level measurements during first-line chemotherapy predict response to treatment among ovarian cancer patients?
Chudecka-Głaz A; Cymbaluk-Płoska A; Wężowska M; Menkiszak J
PLoS One; 2018; 13(3):e0194270. PubMed ID: 29584739
[TBL] [Abstract] [Full Text] [Related]
4. Kinetic modeling and efficacy of intraperitoneal paclitaxel combined with intravenous cyclophosphamide and carboplatin as first-line treatment in ovarian cancer.
Hofstra LS; Bos AM; de Vries EG; van der Zee AG; Willemsen AT; Rosing H; Beijnen JH; Mulder NH; Aalders JG; Willemse PH
Gynecol Oncol; 2002 Jun; 85(3):517-23. PubMed ID: 12051884
[TBL] [Abstract] [Full Text] [Related]
